Hayder Saeed

Feb 28, 2024 | onclive.com | Hayder Saeed

February 28, 2024Hayder Saeed, MD, discusses key takeaways regarding the use of polatuzumab vedotin plus R-CHP in diffuse large B-cell lymphoma.

Dec 18, 2023 | opmed.doximity.com | Casey Paul Schukow |Hayder Saeed |Lynne Lederman |Jordan Frey

When I first began medical school, I never considered there would come a day when I would perform a fetal autopsy. Several weeks into my first year of pathology residency, however, duty called – my first-ever fetal autopsy was upon me. For anyone reading this, you must understand several important pieces about me as I entered this life-changing experience. First, I was facing burnout that began during my previous year as a medicine intern.

Dec 18, 2023 | opmed.doximity.com | Hayder Saeed |Lynne Lederman |Jordan Frey |Benjamin Wade Frush

Unleashing the Spark: My Top #ASH23 Posts That Ignited EngagementTwitter proved my secret weapon for connecting with fellow hematology/oncology minds at the American Society of Hematology (ASH) annual meeting this year! This year, I opted for a digital approach, trading notepads for Twitter threads to connect with attendees and navigate the vast scientific ocean. But with so many talks, selecting the most impactful ones became a conundrum.

Dec 18, 2023 | opmed.doximity.com | Lynne Lederman |Hayder Saeed |Jordan Frey |Benjamin Wade Frush

Banu Aygun, MD, presented long-term follow-up data from the Realizing Effectiveness Across Continents with Hydroxyurea (REACH) trial at the plenary session. The phase 1/2, open-label, REACH is the largest trial to test hydroxyurea in children worldwide, and among the first to test its feasibility in real-world settings in Africa. Primary study results she presented at the 2018 ASH plenary session showed the study was feasible for enrollment, retention, and adherence.

Oct 31, 2023 | targetedonc.com | Hayder Saeed

Hayder Saeed, MD, an associate member in the department of malignant hematology at the Moffit Cancer Center in Tampa, Florida, discusses the mechanism of action of tafasitamab-cxix (Monjuvi) when used to treat patients with diffuse large B-cell lymphoma (DLBCL). The CD19-directed cytolytic antibody was given an accelerated approval by the FDA in 2020 based off the results of the L-MIND study (NCT02399085), which looked at the use of tafasitamab in combination with lenalidomide (Revlimid).